Public Biotech Executive Compensation Advisory

Board-level compensation intelligence built around a specific decision.

GeneCoda® combines SEC-filed executive compensation disclosures, governed peer selection, and life-sciences leadership judgment to help Boards, Compensation Committees, CEOs, CHROs, and investors make better executive compensation decisions.

Public-company compensation disclosures can answer what an executive was paid. They do not automatically answer whether that executive is an appropriate comparator.

GeneCoda® evaluates compensation in the context of:

  • Executive role

  • Company stage

  • Company scale

  • Revenue status

  • Operating complexity

  • Leadership mandate

  • Source-period comparability

Why this Analysis Is Different

  • SEC-filed source data

  • Governed peer selection

  • Explicit comparability treatment

  • Visible sample-size discipline

  • Board-ready decision support

Executive compensation data are easy to find.

Comparable evidence is harder.

Primary Interest
Role being evaluated

Two Ways to Engage GeneCoda®

Boardroom Compensation Benchmark

One executive. One principal decision.

Hiring & offer calibration

 

Retention & promotion

 

Succession & incumbent review

 

~10 business days

 
$12,500

Executive Leadership Team Compensation Review

Up to five executives. Integrated leadership-team review.

Annual Compensation Committee review

 

External competitiveness

 

Internal coherence & forward retention

 

~15–20 business days

 
$45,000

Seeking a broader market view first?

About GeneCoda®

GeneCoda® is a retained executive search and leadership advisory firm focused exclusively on life sciences. We help biotechnology, pharmaceutical, medical device, diagnostics, and life sciences tools companies make consequential leadership decisions through executive search, talent intelligence, market mapping, and compensation insight.